Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies

Area of Science:

• Epigenetics and Molecular Biology
• Oncology and Cancer Therapeutics
• Immunology

Background:

• Histone deacetylation is a key epigenetic mechanism regulating gene transcription.
• Overexpression of histone deacetylases (HDACs) is common in many cancers.
• The tumor microenvironment significantly influences cancer development and progression.

Purpose of the Study:

• To explore how HDAC inhibitors regulate cancer progression through the tumor microenvironment.
• To investigate the mechanisms by which HDAC inhibitors suppress tumor growth.
• To examine the synergistic effects of combined drug therapies involving HDAC inhibitors.

Main Methods:

• Review of existing literature on HDAC inhibitors, cancer epigenetics, and tumor microenvironment.
• Analysis of pathways involved in HDAC inhibitor-mediated tumor suppression.
• Exploration of preclinical and clinical data on combination therapies.

Main Results:

• HDAC inhibitors can enhance tumor immune antigenicity, potentially slowing tumor progression.
• HDAC inhibitors modulate the tumor microenvironment, impacting cancer cell proliferation.
• Combined therapies involving HDAC inhibitors demonstrate synergistic effects in preclinical models.

Conclusions:

• HDAC inhibitors represent a promising therapeutic strategy for various cancers.
• Targeting the tumor microenvironment with HDAC inhibitors offers a viable approach for cancer treatment.
• Combination therapies hold significant potential for improving treatment efficacy.